000130679 001__ 130679
000130679 005__ 20240130150402.0
000130679 0247_ $$2doi$$a10.1016/j.clnu.2020.02.036
000130679 0248_ $$2sideral$$a117350
000130679 037__ $$aART-2020-117350
000130679 041__ $$aeng
000130679 100__ $$0(orcid)0000-0002-7758-3588$$aSanz-París, Alejandro$$uUniversidad de Zaragoza
000130679 245__ $$aDiabetes-specific formulas high in monounsaturated fatty acids and metabolic outcomes in patients with diabetes or hyperglycaemia. A systematic review and meta-analysis
000130679 260__ $$c2020
000130679 5060_ $$aAccess copy available to the general public$$fUnrestricted
000130679 5203_ $$aObjective: The aim of this study was to compare the metabolic benefits of diabetes-specific formulas (DSF) high in monounsaturated fatty acids (MUFA) with standard formulas (STDF) in adult patients with type 1, type 2 diabetes or stress-induced hyperglycaemia. Research design and methods: A systematic review and meta-analysis were conducted through a literature search using different electronic databases from the index date to December 2018. We included randomised controlled trials that assessed the health benefits of high MUFA DSF vs STDF. Included outcomes were glycaemic control, lipid metabolism and tolerance. Effect sizes were calculated as standardised mean differences (SMDs) (<0.4 were considered small, 0.4–0.7 moderate and >0.7 large). This systematic review was registered as CRD42018108931 on Prospero. Results: Of 385 references reviewed, 18 studies involving 845 adults met our inclusion criteria and contributed to the meta-analysis. Use of a high MUFA DSF compared with a STDF was associated with a statistically significant decrease in peak of postprandial glucose [SMD -1.53, 95% confidence interval (CI) -2.44 to -0.61], incremental glucose response (SMD -1.19, 95% CI -1.71 to -0.68), area under the curve of plasma insulin (SMD -0.65, 95% CI -1.03 to -0.26), mean blood glucose level (SMD -0.41, 95% CI -0.63 to -0.19), glycosylated haemoglobin (HbA1c) change (SMD -0.63, 95% CI -1.21 to -0.05), glucose variability (SMD -0.93, -1.55 to -0.31), mean administered insulin dose (SMD -0.49, 95% CI -0.85 to -0.14), mean blood triglycerides (SMD -0.34, 95% CI -0.65 to -0.03) and increase of mean blood high-density lipoproteins (SMD +0.42, 95% CI 0.08 to 0.76). Non-significant differences were found for tolerance [odds ratio (OR) 0.95, 95% CI 0.87 to 1.05]. Conclusions: This meta-analysis shows that a DSF (oral supplements and tube feeds) high in MUFAs can improve glucose control and metabolic risk factors among patients with diabetes or stress-induced hyperglycaemia compared with a STDF.
000130679 536__ $$9info:eu-repo/grantAgreement/ES/ISCIII-FEDER/PI17-1732
000130679 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000130679 590__ $$a7.324$$b2020
000130679 591__ $$aNUTRITION & DIETETICS$$b7 / 87 = 0.08$$c2020$$dQ1$$eT1
000130679 592__ $$a1.915$$b2020
000130679 593__ $$aNutrition and Dietetics$$c2020$$dQ1
000130679 593__ $$aCritical Care and Intensive Care Medicine$$c2020$$dQ1
000130679 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000130679 700__ $$aMatía-Martín, Pilar
000130679 700__ $$aMartín-Palmero, Ángela
000130679 700__ $$aGómez-Candela, Carmen
000130679 700__ $$aCamprubi Robles, María
000130679 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000130679 773__ $$g39, 11 (2020), 3273-3282$$pClin. nutr.$$tClinical Nutrition$$x0261-5614
000130679 8564_ $$s1097389$$uhttps://zaguan.unizar.es/record/130679/files/texto_completo.pdf$$yPostprint
000130679 8564_ $$s1209233$$uhttps://zaguan.unizar.es/record/130679/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000130679 909CO $$ooai:zaguan.unizar.es:130679$$particulos$$pdriver
000130679 951__ $$a2024-01-30-14:07:05
000130679 980__ $$aARTICLE